GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G Unic^TM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.

Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs.

Read the full press release.